Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma

BACKGROUND: Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced expiratory volume in 1 s (FEV(1)) in patients with moderate‐to‐severe asthma and elevated type 2 biomarkers from phase 3 LIBERTY ASTHMA QUEST (NCT0...

Descripción completa

Detalles Bibliográficos
Autores principales: Papi, Alberto, Corren, Jonathan, Castro, Mario, Domingo, Christian, Rogers, Linda, Chapman, Kenneth R., Jackson, Daniel J., Daizadeh, Nadia, Pandit‐Abid, Nami, Gall, Rebecca, Jacob‐Nara, Juby A., Rowe, Paul J., Deniz, Yamo, Ortiz, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087924/
https://www.ncbi.nlm.nih.gov/pubmed/35899469
http://dx.doi.org/10.1111/all.15456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087924/
https://www.ncbi.nlm.nih.gov/pubmed/35899469
http://dx.doi.org/10.1111/all.15456

Ejemplares similares